Genetic analysis of CYP2C9 polymorphism in a Japanese population

Pharmacogenetics

Volumn 7, Issue 5, 1997, Pages 405-409

  Nasu, Kayoko ^a   Kubota, Takahiro ^a   Ishizaki, Takashi ^b  

^a SRL INC   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

CYP2C9; Genotyping; Japanese; Polymorphism

Indexed keywords

CYTOCHROME P450;

DRUG METABOLISM; ENZYME ACTIVITY; ETHNOLOGY; FREQUENCY ANALYSIS; GENETIC ANALYSIS; GENOTYPE; HUMAN; JAPAN; PRIORITY JOURNAL; SHORT SURVEY; STATISTICS;

ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; JAPAN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0030868490     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199710000-00011     Document Type: Short Survey

References (32)

1. Brockmöller J, Roots I. Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 1994: 27, 246-248.
2. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther 1993: 57, 129-160.
3. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 1990: 46, 377-394.
4. Ged C, Umbenhauer DR, Bellew TM, Bork RW, Srivastava PK, Shinriki N, Lloyd RS, Guengerich FP. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P450 (S)-mephenytoin 4′-hydroxylase. Biochemistry 1988: 27, 6929-6940.
5. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994: 4, 285-299.
6. Goldstein JA, Feletto MB, Romkes-Sparks M, Sullivan T, Raucy JL, Kitareewan S, Lasker JM, Ghanayem B. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 1994: 33, 1743-1752.
7. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem. 1992: 267, 83-90.
8. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar D, Goldstein JA. Correlation of human P4502C substrate specifities with primary structure: Warfarin as a probe. Mol Pharmacol 1993: 43, 234-239.
9. Kimura S, Pastewka J, Gelboin HV, Gonzalez FJ. cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Nucleic Acids Res 1987: 15, 10053-10054.
10. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient parahydroxylation as the cause of diphenylhydantoin toxicity. Neurology 1964: 14, 542-548.
11. Leeman T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 1993: 52, 29-34.
12. Meehan RR, Gosden JR, Rout D, Hastle ND, Freidberg T, Adesnik M, Buckland R, van Heyningen V, Fletcher J, Spurr NK et al. Human cytochrome P-450 PB-1: A multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am J Hum Genet 1988: 42, 26-37.
13. Miners JO, Wing LMH, Birkett DJ. Normal metabolism of debrisoquine and theophylline in a poor hydroxylator of tolbutamide. Aust NZ J Med 1985: 15, 348-349.
14. Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 1995: 272, 1076-1081.
15. Page MA, Boutagy JS, Shenfield GM. A screening test for slow metabolisers of tolbutamide. Br J Clin Pharmacol 1991: 31, 649-654.
16. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990: 252, 442-447.
17. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WE. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin drug interactions. Chem Res Toxicol 1992: 5, 54-59.
18. Rettie A, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994: 4, 39-42.
19. 14C] naproxen O-demethylase activity in human liver microsomes. Evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Dispos 1996: 24, 126-136.
20. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991: 30, 3247-3255.
21. Srivastava PK, Yun C-H, Beaune PH, Ged C, Guengerich FP. Separation of human liver microsomal tolbutamide hydroxylase and (S)-Mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 1991: 40, 69-79.
22. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996: 6, 429-439.
23. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996: 6, 341-349.
24. Umbenhauer DR, Martin MV, Lloyd RS, Guengerich FP. Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. Biochemistry 1987: 26, 1094-1099.
25. Vasco MR, Dell RD, Daly DD, Pippenger CE. Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther 1980: 27, 96-103.
26. Vermeij P, Ferrari MD, Buruma OJ, Veenema H, de Wolf FA. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family. Clin Pharmacol Ther 1988: 44, 588-593.
27. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991: 175, 1112-1118.
28. Veronese ME, Miners JO, Rees DLP, Birkett DJ. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. Pharmacogenetics 1993a: 3,86-93.
29. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DLP, Gasser R, Meyer UA, Birkett DJ. Site-directed mutation studies of human liver cytochrome P-450 isozymes in the CYP2C subfamily. Biochem J 1993b: 289, 533-538.
30. Wang SL, Huang JD, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995: 5, 37-42.
31. Yasumori T, Kawano S, Nagata K, Shimada M, Yamazoe Y, Kato R. Nucleotide sequence of a human liver cytochrome P450 related to the rat male specific forms. J Biochem 1987: 102, 1075-1082.
32. Zhao J, Leeman T, Dayer P. In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Life Sci 1992: 51, 575-581.